| Ident. | Authors (with country if any) | Title |
|---|
| 001135 (2013) |
Prabha Ranganathan [États-Unis] | Herpes zoster infection risk in patients with rheumatoid arthritis on tumour necrosis factor inhibitors |
| 001137 (2013) |
Claudia Ravaglia [Italie] ; Carlo Gurioli [Italie] ; Gian Luca Casoni [Italie] ; Silvia Asioli [Italie] ; Venerino Poletti [Italie] | Fever, splenomegaly and lymphopenia in sarcoidosis |
| 001146 (2013) |
Inbal Braunstein [États-Unis] ; Victoria Werth [États-Unis] | Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy |
| 001215 (2013) |
S. Kamali ; S. Pay ; N. Inanc ; I. Simsek ; V. Hamuryudan [Turquie] | FRI0193 Current therapy of rheumatoid arthritis in turkey: rheumatologists’ perspective |
| 001249 (2013) |
| Abstracts |
| 001325 (2012) |
Haider M. Al Attia ; Mohamed Abushawish | Treatment with tocilizumab leads to the disappearance of olecranon rheumatoid nodules |
| 001333 (2012) |
Sara C. Hyoun ; Sarah G. Obi An ; Anthony R. Scialli [États-Unis] | Teratogen update: Methotrexate |
| 001379 (2012) |
Christina Lam [États-Unis, Canada] ; Ruth Ann Vleugels [États-Unis] | Management of cutaneous dermatomyositis |
| 001406 (2012) |
Fiona L. Dignan [Royaume-Uni] ; Persis Amrolia [Royaume-Uni] ; Andrew Clark [Royaume-Uni] ; Jacqueline Cornish [Royaume-Uni] ; Graham Jackson [Royaume-Uni] ; Prem Mahendra [Royaume-Uni] ; Julia J. Scarisbrick [Royaume-Uni] ; Peter C. Taylor [Royaume-Uni] ; Bronwen E. Shaw [Royaume-Uni] ; Michael N. Potter [Royaume-Uni] | Diagnosis and management of chronic graft‐versus‐host disease |
| 001409 (2012) |
Christopher B. Hansen [États-Unis] ; Kevin W. Dahle [États-Unis] | Cutaneous lupus erythematosus |
| 001411 (2012) |
Sengwee Toh [États-Unis] ; Lingling Li [États-Unis] ; Leslie R. Harrold [États-Unis] ; Elizabeth A. Bayliss [États-Unis] ; Jeffrey R. Curtis [États-Unis] ; Liyan Liu [États-Unis] ; Lang Chen [États-Unis] ; Carlos G. Grijalva [États-Unis] ; Lisa J. Herrinton [États-Unis] | Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? |
| 001441 (2012) |
Larry W. Moreland [États-Unis] ; James R. O'Dell ; Harold E. Paulus ; Jeffrey R. Curtis ; Joan M. Bathon [États-Unis] ; E. William St. Clair [États-Unis] ; S. Louis Bridges Jr. ; Jie Zhang ; Theresa Mcvie ; George Howard ; Désirée Van Der Heijde [Pays-Bas] ; Stacey S. Cofield | A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial |
| 001481 (2011) |
W G Dixon [Royaume-Uni, Canada] ; A. Kezouh [Canada] ; S. Bernatsky [Canada] ; S. Suissa [Canada] | The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case–control study |
| 001482 (2011) |
Naomi B. Klarenbeek [Pays-Bas] ; Melek Güler-Yüksel [Pays-Bas] ; Sjoerd M. Van Der Kooij [Pays-Bas] ; K Huub Han [Pays-Bas] ; H Karel Ronday [Pays-Bas] ; Pit J S M. Kerstens [Pays-Bas] ; Patrick E H. Seys [Pays-Bas] ; Tom W J. Huizinga [Pays-Bas] ; Ben A C. Dijkmans [Pays-Bas] ; Cornelia F. Allaart [Pays-Bas] | The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study |
| 001517 (2011) |
C. Domingo [Espagne, Canada] ; A. Moreno [Espagne] ; R. Mirapeix [Espagne] | Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids |
| 001535 (2011) |
Antoni Bennàssar [Espagne] ; Antoni Mas [Espagne] ; Antonio Guilabert [Espagne] ; Marc Julià [Espagne] ; José Manuel Mascar Aly [Espagne] ; Carmen Herrero [Espagne] | Multicentric reticulohistiocytosis with elevated cytokine serum levels |
| 001548 (2011) |
Yvonne E. Chiu [États-Unis] ; Dominic O. Co [États-Unis] | Juvenile Dermatomyositis: Immunopathogenesis, Role of Myositis‐Specific Autoantibodies, and Review of Rituximab Use |
| 001564 (2011) |
K. Montag [Australie] ; M. Gingold [Australie] ; A. Boers [Australie] ; G. Littlejohn [Australie] | Disease‐modifying anti‐rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community‐based practice |
| 001569 (2011) |
Yiyun Yu [États-Unis, République populaire de Chine] ; Antonio La Cava [États-Unis] | Current drugs in systemic lupus erythematosus |
| 001577 (2011) |
| Bristol Cup Posters |
| 001588 (2011) |
| ARA Scientific Posters |
| 001635 (2010) |
Naomi B. Klarenbeek [Pays-Bas] ; Pit J S M. Kerstens [Pays-Bas] ; Tom W J. Huizinga [Pays-Bas] ; Ben A C. Dijkmans [Pays-Bas] ; Cornelia F. Allaart [Pays-Bas] | Recent advances in the management of rheumatoid arthritis |
| 001641 (2010) |
Kimberly P. Liang [États-Unis] ; Elena Myasoedova [États-Unis] ; Cynthia S. Crowson [États-Unis] ; John M. Davis [États-Unis] ; Véronique L. Roger [États-Unis] ; Barry L. Karon [États-Unis] ; Daniel D. Borgeson [États-Unis] ; Terry M. Therneau [États-Unis] ; Richard J. Rodeheffer [États-Unis] ; Sherine E. Gabriel [États-Unis] | Increased prevalence of diastolic dysfunction in rheumatoid arthritis |
| 001682 (2010) |
| Poster and Oral Abstracts |
| 001700 (2010) |
Anand N. Malaviya [Inde] ; Amit Sharma [Inde] ; Divya Agarwal [Inde] ; Sanjiv Kapoor [Inde] ; Shriram Garg [Inde] ; Sujata Sawhney [Inde] | Low‐dose and high‐dose methotrexate are two different drugs in practical terms |
| 001739 (2010) |
| Case Report |
| 001754 (2010) |
| 2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy |
| 001790 (2009) |
Shahir S. Hamdulay [Royaume-Uni] ; Justin C. Mason [Royaume-Uni] | Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA? |
| 001810 (2009) |
Catherine A. Heyneman [États-Unis] | Systemic Lupus Erythematosus: A Therapeutic Update |
| 001848 (2009) |
N. Varatharajan [Australie] ; I. G. S. Lim ; A. Anandacoomarasamy ; R. Russo ; K. Byth [Australie] ; D. G. Spencer ; N. Manolios ; G. B. Howe [Australie] | Methotrexate: long‐term safety and efficacy in an Australian consultant rheumatology practice |
| 001853 (2009) |
C. Salliot [France] ; D. Van Der Heijde [Pays-Bas] | Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research |
| 001865 (2009) |
R. Smith [Royaume-Uni] ; J. Haeney [Royaume-Uni] ; Kh. Gulraiz Rauf [Royaume-Uni] | Improving cosmesis of lupus pernio by excision and forehead flap reconstruction |
| 001880 (2009) |
Alexander Kreuter [Allemagne] ; Thomas Krieg [Allemagne] ; Margitta Worm [Allemagne] ; Jörg Wenzel [Allemagne] ; Thilo Gambichler [Allemagne] ; Annegret Kuhn [Allemagne] ; Elisabeth Aberer [Allemagne] ; Karin Scharffetter-Kochanek [Allemagne] ; Nicolas Hunzelmann [Allemagne] | Diagnosis and Therapy of Localized Scleroderma |
| 001888 (2009) |
Efstratios Panselinas [Grèce] ; J. Keith Rodgers [États-Unis] ; Marc A. Judson | Clinical outcomes in sarcoidosis after cessation of infliximab treatment |
| 001959 (2008) |
S. Bernatsky [Canada] ; L. Joseph [Canada] ; J-F Boivin [Canada] ; C. Gordon [Canada] ; M. Urowitz [États-Unis] ; D. Gladman [États-Unis] ; P R Fortin [États-Unis] ; E. Ginzler [Corée du Sud] ; S-C Bae [Canada] ; S. Barr [Royaume-Uni] ; S. Edworthy [Royaume-Uni] ; D. Isenberg [États-Unis] ; A. Rahman [États-Unis] ; M. Petri [États-Unis] ; G S Alarc N [États-Unis] ; C. Aranow [États-Unis] ; M-A Dooley [Canada] ; R. Rajan [Canada] ; J-L Sénécal [Canada] ; M. Zummer [États-Unis] ; S. Manzi [États-Unis] ; R. Ramsey-Goldman [Canada, Royaume-Uni, États-Unis, Corée du Sud] ; A E Clarke [Canada] | The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case–cohort study |
| 001962 (2008) |
A. Hamprecht [Allemagne] ; T. Tüting [Allemagne] ; T. Bieber [Allemagne] ; J. Wenzel [Allemagne] | Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab |
| 001968 (2008) |
Robert Kim [États-Unis] ; Keith C. Meyer | Review: Therapies for interstitial lung disease: past, present and future |
| 001982 (2008) |
Mohd Shahrir ; Mohd Shahdan ; Mohamed Shahid ; W. Sulaiman ; A. M. Mokhtar ; M. Othman ; A. Rosman ; S. G. Ong ; I. S. Lau ; M. M. Zain ; H. Yusof ; A. Ismail ; A. Yusof ; B. E. Tan ; H. C. Chong ; H. Hussein ; M. Eishwary ; N. A. Shahril ; M. I. Liza ; S. C. Gun ; Y. L. Loh ; B. De'Souza ; A. Yusof | Multicentre survey of rheumatoid arthritis patients from Ministry of Health Rheumatology Centers in Malaysia |
| 001A08 (2008) |
A. Delluc [France] ; N. Limal [France] ; X. Puéchal [France] ; C. Francès [France] ; J C Piette [France] ; P. Cacoub [France] | Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome |
| 001A10 (2008) |
Michael Sticherling [Allemagne] ; Gisela Bonsmann [Allemagne] ; Annegret Kuhn [Allemagne] | Diagnostic approach and treatment of cutaneous lupus erythematosus |
| 001B32 (2007) |
R N Jois [Royaume-Uni] ; K. Gaffney [Royaume-Uni] ; P. Cane [Royaume-Uni] ; A G Nicholson [Royaume-Uni] ; A C Wotherspoon [Royaume-Uni] | Methotrexate‐associated lymphoproliferative disorder masquerading as interstitial lung disease |
| 001B37 (2007) |
P. S. Arul Rajamurugan [Inde] ; C. Panchapakesa Rajendran [Inde] ; S. Rukmangatharajan [Inde] ; S. Rajeswari [Inde] ; R. Ravichandran [Inde] | Leflunomide‐induced nodulosis in a case of Rheumatoid arthritis |
| 001B42 (2007) |
Joerg Wenzel [Allemagne] ; Thomas Tüting [Allemagne] | Identification of type I interferon‐associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches |
| 001B71 (2007) |
Lester E. Mertz [États-Unis] ; Janis E. Blair [États-Unis] | Coccidioidomycosis in Rheumatology Patients |
| 001B84 (2007) |
G. Ruiz-Irastorza [Espagne] ; A. Ugarte [Espagne] ; M V Egurbide [Espagne] ; M. Garmendia [Espagne] ; J I Pijoan [Espagne] ; A. Martinez-Berriotxoa [Espagne] ; C. Aguirre [Espagne] | Antimalarials may influence the risk of malignancy in systemic lupus erythematosus |
| 001B88 (2007) |
Gerd R. Burmester [Allemagne] ; Xavier Mariette [France] ; Carlomaurizio Montecucco [Italie] ; Indalecio Monteagudo-Sáez [Espagne] ; Michel Malaise [Belgique] ; Athanasios G. Tzioufas [Grèce] ; Johannes W J. Bijlsma [Pays-Bas] ; Kristina Unnebrink [Allemagne] ; Sonja Kary [Allemagne] ; Hartmut Kupper [Allemagne] | Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial |
| 001C32 (2006) |
I. Fomin [Israël] ; D. Caspi [Israël] ; V. Levy [Israël] ; N. Varsano [Israël] ; Y. Shalev [Israël] ; D. Paran [Israël] ; D. Levartovsky [Israël] ; I. Litinsky [Israël] ; I. Kaufman [Israël] ; I. Wigler [Israël] ; E. Mendelson [Israël] ; O. Elkayam [Israël] | Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers |
| 001C33 (2006) |
| VASCULITIS |
| 001C35 (2006) |
A C Cordeiro [Portugal] ; D A Isenberg [Royaume-Uni] | Treatment of inflammatory myopathies |
| 001C44 (2006) |
B. Y. H. Thong ; S. Vasoo [Singapour] ; E. T. Koh | The use of anti‐tumour necrosis factor‐α therapies for rheumatoid arthritis in Singapore |
| 001C46 (2006) |
Chris Deighton [Royaume-Uni] ; Kate Gadsby [Royaume-Uni] | The new British Society for Rheumatology disease modifying anti‐rheumatic drugs guidelines |
